[Ткачёва ОН—д. м. н., профессор, директор ФГАОУ ВО" Российский национальный
исследовательский медицинский университет им. НИ Пирогова" Минздрава России …

Background: Bivalirudin was not superior to unfractionated heparin in patients with
myocardial infarction (MI) treated with percutaneous coronary intervention and no planned …

A few decades ago, the understanding of the pathophysiological processes involved in the
coronary artery thrombus formation has placed anticoagulant and antiplatelet agents at the …

Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-
care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered …

Acute myocardial infarction (AMI) is a fatal manifestation of ischemic heart disease and
remains a major public health concern worldwide despite advances in its diagnosis and …

Localized drug delivery with sustained elution characteristics from nanocarrier coated stents
represents a viable therapeutic approach to circumvent concerns related to coronary stent …

Heparin and bivalirudin are widely used as anticoagulants in the setting of acute thrombosis.
In this study, we investigated how these drugs affect the ability of thrombin to generate a …

Background. Thrombocytopenia was intuitively considered to be associated with higher risk
of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI) …

Current treatments for acute myocardial infarction (AMI) have dramatically improved clinical
outcomes during the first year after AMI. Less is known, however, about the subsequent risks …

Abstract Background Although the European Medicines Agency and the US Food and Drug
Administration have, respectively, approved rivaroxaban for the prevention of recurrent …